APELOA(SZ:000739)2022-03-09 16:00Financial Performance - The total revenue for 2021 was ¥8,942,618,232.82, representing a 13.49% increase compared to ¥7,879,672,743.47 in 2020[11]. - The net profit attributable to shareholders was ¥955,550,170.21, up 17.00% from ¥816,730,067.12 in the previous year[11]. - The net profit after deducting non-recurring gains and losses was ¥833,083,068.11, reflecting a 20.53% increase from ¥691,196,908.38 in 2020[11]. - The basic earnings per share for 2021 was ¥0.8108, a 17.00% increase compared to ¥0.6930 in 2020[11]. - The total revenue for the first quarter was ¥1,966,705,576.05, with a peak in the fourth quarter at ¥2,543,464,846.12, reflecting a quarterly growth of approximately 29%[14]. - Net profit attributable to shareholders in the second quarter reached ¥336,250,963.73, while the fourth quarter saw a decline to ¥193,416,570.79, indicating a year-over-year decrease of about 43%[14]. - The company achieved a gross profit of CNY 125,327.10 million, with a gross margin of 19.15%[28]. - The CDMO business generated revenue of CNY 139,392.68 million, a year-on-year increase of 32.09%, with a gross profit of CNY 60,108.73 million and a gross margin of CNY 43.12%[28]. - The company's formulation business reported revenue of CNY 86,743.45 million, a 14.11% increase year-on-year, with a gross profit of CNY 49,810.79 million and a gross margin of 57.42%[28]. Assets and Liabilities - The total assets at the end of 2021 amounted to ¥9,163,329,850.05, a 22.26% increase from ¥7,494,787,957.34 at the end of 2020[11]. - The net assets attributable to shareholders were ¥5,060,005,493.00, which is a 15.24% increase from ¥4,390,675,233.32 in 2020[12]. - The company's total liabilities reached ¥4,103,324,357.05, up from ¥3,104,112,724.02, marking a growth of around 32.2%[167]. - The total equity attributable to shareholders increased to ¥5,060,005,493.00 from ¥4,390,675,233.32, showing a rise of about 15.2%[168]. - Accounts receivable amounted to ¥1,446,516,969.93, representing 15.79% of total assets, an increase of 1.33% from the previous year[48]. - The company's total liabilities were ¥363,483,300.68 in 2021, an increase from ¥292,812,732.79 in 2020, reflecting a rise of 24.1%[171]. Cash Flow - The net cash flow from operating activities was ¥611,748,728.68, down 42.26% from ¥1,059,526,132.55 in 2020[11]. - The net cash flow from investment activities dropped significantly by 584.55%, resulting in a net outflow of ¥515,391,145.01 in 2021[46]. - The cash and cash equivalents at the end of the reporting period were ¥2,610,010,623.44, accounting for 28.48% of total assets, a slight decrease of 0.80% from the previous year[48]. - The cash flow from financing activities resulted in a net outflow of approximately ¥204.32 million in 2021, contrasting with a net inflow of approximately ¥78.75 million in 2020[180]. Research and Development - The company invested a total of 479 million CNY in R&D in 2021, representing a year-on-year increase of 34.88% and accounting for 5.36% of total revenue[22]. - The company submitted 14 invention patent applications and received 13 invention patent authorizations during the reporting period, with a total of 131 valid patents by the end of the period[22]. - The company has a total of 879 R&D personnel, including 46 PhDs and 192 Masters, emphasizing its commitment to innovation-driven development[25]. - Research and development expenses increased by 27.47% to 446,219,087.77 CNY in 2021, compared to 350,055,448.09 CNY in 2020[39]. Market and Industry Position - The pharmaceutical manufacturing industry is undergoing significant reforms, with an average price reduction of 53% in selected drugs due to centralized procurement initiatives[19]. - The company has achieved notable rankings, including 40th in the "Top 100 Pharmaceutical Enterprises" by the Ministry of Industry and Information Technology in 2020[21]. - The company has established strategic partnerships with over 30 domestic innovative drug companies to enhance its CDMO business[28]. - The company has a global marketing network covering over 70 countries and regions, with a strong presence in North America, Europe, and Asia[25]. Governance and Compliance - The company maintains independence from its controlling shareholders in terms of assets, personnel, and financial operations[62]. - The internal audit department conducted an audit focusing on high-risk areas, providing preventive corrective measures based on findings[60]. - The company emphasizes compliance and governance through its board structure and independent directors[68]. - The company has not faced any major litigation or arbitration matters during the reporting period[124]. Environmental Responsibility - The company is classified as a key pollutant discharge unit, with total COD emissions of 285.19 tons, well below the regulatory limit of 500 mg/L[107]. - The company has implemented a self-inspection and correction process in accordance with the "Special Action Checklist for Listed Company Governance" to enhance governance practices[106]. - The company has invested approximately CNY 37.52 million to enhance wastewater pollution prevention capabilities, ensuring stable and compliant discharge of wastewater[109]. - The company has implemented a "zero direct discharge" transformation for wastewater, actively promoting rainwater and sewage diversion[109]. Shareholder Information - The company plans to distribute a cash dividend of ¥2.85 per 10 shares, based on a total of 1,178,523,492 shares[1]. - The company distributed cash dividends amounting to 35% of the distributable profits in recent years, ensuring shareholder returns[118]. - The total number of shares for the company is 1,178,523,492, with 99.99% being unrestricted shares[139]. - The largest shareholder, Hengdian Group Holdings Co., Ltd., holds 28.08% of the shares, totaling 330,941,729 shares, which are pledged[140].